Revolutionizing Drug Discovery: Advances in AI and Machine Learning

Dr. Nirmala V.Shinde, Ph.D., Associate Professor, Department of Pharmaceutical Chemistry, SMBT College Of Pharmacy, Igatpuri,Nashik,India.Affiliated to Savitribai Phule Pune University, Dhamangaon, Nashik, Maharashtra-422403 India..

Ms Vrushali P. Patole**,**Department of Pharmaceutical Chemisrty , SMBT college of Pharmacy , Affiliated to Savitribai Phule Pune University, Dhamangaon, Nashik, Maharashtra-422403 India..

Ms Siddhi M. Chandak ,Department of Pharmaceutical Chemisrty , SMBT college of Pharmacy , Affiliated to Savitribai Phule Pune University, Dhamangaon, Nashik, Maharashtra-422403 India..

Address of Corresponding Author: Ms Vrushali P. Patole**,**Department of Pharmaceutical Chemisrty , SMBT college of Pharmacy , Affiliated to Savitribai Phule Pune University, Dhamangaon, Nashik, Maharashtra-422403 India..

Abstract

The integration of artificial intelligence (AI) and machine learning (ML)(1) into drug discovery has markedly enhanced the efficiency, precision, and cost-effectiveness of this inherently complex process. AI-driven methodologies are now pivotal across various stages of Drug development involves target identification, lead compound discovery, and optimization to create effective and safe therapeutic agent drug repurposing, and clinical trial design. Recent advancements such as Deep learning includes techniques such as GANs, a method to synthesize synthetic data; transfer learning, an application for domain adaptation; and XAI to explain AI, with the objective of making AI more interpretable and transparentare reshaping the pharmaceutical landscape by offering innovative solutions to longstanding challenges. This review provides a comprehensive examination of the current progress in AI-driven drug discovery, with a focus on state-of-the-art methodologies, significant breakthroughs, ongoing challenges, and ethical considerations. Supported by an extensive compilation of over 100 references, this work aims to serve as a critical resource for researchers and industry professionals seeking to harness the potential of AI in pharmaceutical innovation.

Keywords: Artificial intelligence, machine learning, drug discovery, generative adversarial networks, deep learning, drug repositioning, computational biology.

1. Introduction

Drug discovery(2) is a difficult and resource-intensive process that often requires more than a decade and billions of dollars todevelop a single therapeutic compound. However, recent advancements in computational biology and data science have instigated a paradigm shift, enabling more rapid and efficient approaches to the creation of drugs. Machine learning (ML) and artificial intelligencehave shown the ability to predict molecular interactions, identify therapeutic targets, and optimize lead compounds with high accuracy by leveraging extensive biological and chemical datasets. This review aims to provide an overallanalysis of the transformative role of AI in drug discovery(3), emphasizing both the opportunities and the difficulties related towith its integration. AI is currently applied in the pharmaceutical industry across four major domains, which are discussed in detail below.(4). To ensure accurate analyses and derive meaningful interpretations, the technology leverages an array of advanced statistical models and computational intelligence(5) methodologies. These tools enable the processing of complex, high-dimensional datasets, facilitating robust insights essential for scientific advancements. (6). Deep learning methodologies, characterized by artificial neural networks with multiple hidden processing layers(7), represent a sophisticated approach for modeling complex patterns and relationships within high-dimensional data.(8), (9).Machine learning methods are often considered examples of weak AI. Through the improvement of foundational algorithms and their many applications, they have made great strides.(10).The methodologies relevant to drug discovery, along with computational approaches utilized in computer-aided drug design (CADD)(11), are comprehensively detailed in the treatise Computer-Assisted Drug Design(12). The emergence of artificial intelligence (AI)(13)indicates a change of perspective indrug development, providing a sophisticated array of computational tools that enhance and complement human expertise rather than supplant it(14)(15)(16).

2. **Applications of AI and ML Identification and confirmation,Validation of the target**

The integration of artificial intelligence (AI) into medicinal chemistry(17) has attracted considerable attention in recent years, emerging as a promising approach with the potential to significantly transform the pharmaceutical industry (18)(19).

2.1 Target Identification and Validation

Incorporation of AI into medicinal chemistry is one such promising strategy,which may soon revolutionize the pharmaceutical industry and has recently caught much attention(20)(21).

Techniques: Deep learning frameworks, including Graph Neural Networks (GNNs),

have been increasingly used for the prediction of protein-protein interactions, which provides better predictive capabilities in this domain(22).

Example: Alpha Fold2, developed by Deep Mind, has attained near-experimental accuracy in protein structure prediction, thereby revolutionizing target identification workflows in structural biology(23).

2.2 Virtual Screening and Hit Identification

The advent of machine learning-driven virtual screening has minimized reliance on extensive experimental screening, saving much time and resources. Recently, several approaches have been developed to facilitate ultra-large library virtual screening, such as creating scalable platforms that allow for the parallelization of docking simulations across high-performance computing clusters(24)(25).

Techniques: These mainly include neural networks,Random Forests and support vector machines(26).

Example: The AtomNet deep learning framework has effectively identified relevant medication options for the management of Ebola, demonstrating its utility in computational drug discovery(27).



Figure 1.: **Virtual screening process**(28)**.**

Virtual screening is a computational approach(29) **used in the drug discovery pipeline to identify potential bioactive compounds**(30).

2.3 Lead Optimization

AI models optimize pharmacokinetic properties while minimizing toxicity, streamlining lead optimization.

Techniques: GANs and Variational Auto encoders (VAEs) for de novo molecule design.

Example: The REINVENT platform employs reinforcement learning techniques for iterative molecular design, facilitating the optimization of chemical structures in drug development(31).



Figure 2 : Computer-aided drug design(32) **techniques used in lead discovery and optimization**(33)**.**

After the identification of lead compound, it must undergo systematic modifications to achieve the desired pharmacological and physicochemical propertie(34). High Throughput Screening (35)is a A commonly employed lead discovery approach involves the high-throughput screening of extensive compound libraries to evaluate their potential for interaction with a target of interest.(36).

2.4 Drug Repositioning

Drug repositioning, defined as the investigation of current evidence for existing approved drugs or the advancement of previously studied but unapproved compounds, constitutes a central strategy in drug development. According to certain reports, over 30-40% of novel medications and biologics that the FDA of the United States

approved between 2007 and 2009 can be classified as repurposed or repositioned products(37)(38).

Drug repurposing leverages AI to discover novel applications for already approved medications(39).

Example: The identification of Baricitinib as a potential COVID-19 treatment based on AI has been one of the significant applications of computational methodologies in repurposing existing drugs for emerging diseases(40).Data on Baricitinib safety appear comforting,particularly with respect to thrombotic events, probably because of the short duration of treatment in COVID-19 patients who are simultaneously receiving anticoagulation therapy (41).

Techniques: Logistic regression is one of the machine learning(42) (ML) methods that clustering, are applied to clinical and chemical datasets for meaningful insights(43). Supervised learning and unsupervised learning are two main categories into which techniques can be divided (41).



Figure 3 : Drug Repurposing Example(44)**.**

2.5 Predicting Clinical Trial Outcomes

Artificial intelligence dramatically enhances patient stratification, biomarker discovery, and prediction of clinical trials success rates. Clinical research is divided into interventional and observational studies involving volunteers as participants in assessing the effectiveness and safety of new medications,therapies or medical equipment(45)(46).

Example: IBM Watson Health optimizes clinical trial design through real-world evidence and predictive analytics. In 2013, Watson integrated a vast array of resources, including textbooks such as PubMed and Medline, along with a large dataset of patient records from Memorial Sloan Kettering (47)Cancer Center. According to Forbes (2013), Watson analyzed “605,000 medical symptoms, 25,000 training cases”, and “2 million” clinical notes, utilizing the equivalent of 14,700 clinician hours to ensure accuracy in hypothesis generation. In 2015, IBM launched the IBM Watson Care Manager and Watson Health Cloud for Compliance in life sciences.Also, Watson Health formed strategic partnerships with institutions such as Columbia University, Boston Children's Hospital, ICON plc, Teva Pharmaceuticals, and Sage Bionetworks.(48).

3. Recent Breakthroughs in AI-Driven Drug Discovery

Machine learning and deep learning models(49) facilitate the prediction of drug-target interactions, pharmacological evaluation, and experimental validation. Structure-based drug design methodologies enhance the efficiency of discovering novel therapeutic agents. AI-driven technologies enable the development of personalized treatment strategies(50), tailored to the individual characteristics and disease profiles of patients.(51).

3.1 Generative Models for Molecule Design

Identification of ligands, which are drugs or compounds, for proteins is an important step in drug discovery. For a given protein target, which may represent a human or viral protein, two major methods are generally used to identify potential ligands:

virtual screening and de novo design(52). Virtual screening is the computational assessment of large compound libraries for their potential binding affinity to the target protein.(53).

Generative models, such as GANs and VAEs, have become pivotal in designing novel compounds with desired properties.

Examples: MolGAN, a generative adversarial network (GAN)-based tool for 3D molecular structure generation, has demonstrated considerable potential in designing drug-like molecules. Three-dimensional deep generative models utilize deep neural networks to generate topological representations of molecules, incorporating the 3D coordinates of their constituent atoms. These models are capable of de novo generation of diverse molecular structures.(54)(55).

3.2 AI in Fragment-Based Drug Design (FBDD)(56).

AI-driven fragment-based drug discovery integrates fragment screening with machine learning predictions to identify promising lead compounds. Being a fragment-based approach, FBDD has emerged as a powerful tool in the search for novel pharmaceutical agents, offering a compelling alternative to traditional high-throughput screening (HTS) methods(57) for lead compound identification(58).



Figure 4 :Identification of the target- X-ray crystallography Fragment screening: NMR critical Fragment binding analysis: X-ray

crystallography Fragment growth/linking Lead optimization Preclinical development Clinical trials Regulatory approval(59)**.**

3.3 Quantum Computing and AI Integration

Quantum machine learning (QML) will enable the simulation of complex molecular interactions, thereby improving the accuracy of AI predictions. The application of QML to complex optimization problems, such as those in finance, logistics, and drug discovery, will be made more efficient and feasible. Quantum simulations can potentially reveal the underlying principles of quantum systems, opening the way for breakthroughs in materials science, chemistry, and related fields.(60). Quantum computing, an advanced field that leverages the principles of quantum mechanics to transform computational methodologies, holds significant potential to substantially impact the development and capabilities of artificial intelligence (AI)(61).

3.4 Explainable AI (XAI)

Explainable AI (XAI) tools, such as SHAP (SHapley Additive exPlanations), mitigate the "black-box" nature of machine learning models(62), making AI predictions interpretable. These methods enhance the transparency of AI decision-making processes, thus fostering trust and accountability. Consequently, XAI is increasingly endorsed by governmental bodies and international organizations to ensure compliance with regulatory requirements and to promote the ethical development and deployment of AI systems.(63). Current XAI systems embrace a whole spectrum of dimensions and functionalities, including both enabling relatively basic exploratory data analysis, all the way up to allowing insights into intricate high-dimensional AI models. Such systems aim at covering several degrees of interpretability related both to transparency about the behaviors exhibited by the models as well as clarification of how such complex decisions have been derived using sophisticated architectures for machine learning. (64).

4. Challenges and Limitations

The inefficiency of AI systems in assessment and evaluation(65) is primarily attributed to concerns regarding validity rather than reliability. AI-based scoring mechanisms may, on occasion, yield inaccurate assessments of performance, thereby compromising the validity of the evaluation process. Such discrepancies can arise from the limitations in the model's ability to fully capture the nuanced aspects of the task being assessed, leading to potential misinterpretations of the evaluated outcomes(66).The development of lattice-based machine learning models for the explainable prediction of fertility treatment intervention outcomes represents a significant advancement. However, the efficacy of this research could be substantially enhanced by incorporating studies focused on health center practices related to neonatal intensive care unit (NICU) admissions. Investigating these practices would provide deeper insights into the underlying factors influencing NICU admissions, thereby identifying latent variables that could contribute to the reduction of emergency cases and further refine predictive models(67).

5. Future Perspectives

AI's primary potential in the pharmaceutical sector is to boost productivity and cut expenses.
(68).

6. Conclusion

In conclusion, AI and ML incorporation into drug discovery represents a paradigm shift within pharmaceutical research and development. These technologies facilitate the rapid identification and optimization of potential therapeutic candidates, enable the prediction of pharmacokinetic and pharmacodynamic properties with enhanced accuracy, and significantly reduce the cost and time required for drug development. By addressing existing challenges such as data standardization, algorithmic interpretability, and regulatory compliance, the full potential of AI and ML can be realized. As these methodologies continue to evolve, their transformative impact is poised to drive groundbreaking advancements, streamline the drug discovery pipeline, and ultimately contribute to the global endeavor of improving public health outcomes.

References

1. Tiwari C, Pillai S, Obaid AJ, Saear AR, Sabri AK. Integration of Artificial Intelligence/Machine Learning in Developing and Defending Web Applications. AIP Conf Proc. 2023;2736(1).
2. Singh N, Vayer P, Tanwar S, Poyet JL, Tsaioun K, Villoutreix BO. Drug discovery and development: introduction to the general public and patient groups. Front Drug Discov. 2023;3(May):1–11.
3. Rehman AU, Li M, Wu B, Ali Y, Rasheed S, Shaheen S, et al. Role of Artificial Intelligence in Revolutionizing Drug Discovery. Fundam Res [Internet]. 2024; Available from: https://doi.org/10.1016/j.fmre.2024.04.021
4. Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. Intell Med [Internet]. 2022;2(3):134–40. Available from: https://doi.org/10.1016/j.imed.2021.10.001
5. Tessoni V, Amoretti M. Advanced statistical and machine learning methods for multi-step multivariate time series forecasting in predictive maintenance.

Procedia Comput Sci [Internet]. 2022;200:748–57. Available from: https://doi.org/10.1016/j.procs.2022.01.273

6. Khan MK, Raza M, Shahbaz M, Hussain I, Khan MF, Xie Z, et al. The recent advances in the approach of artificial intelligence (AI) towards drug discovery. Front Chem. 2024;12(May):1–10.
7. Ortiz-rodriguez JM, Vega-carrillo HR, Ortiz-rodríguez JM, Ortiz-rodríguez JM, Martínez-blanco MR, Manuel M. Artificial Neural Networks - Architectures and Applications. Artif Neural Networks - Archit Appl. 2013;(March).
8. Jiménez-Luna J, Grisoni F, Weskamp N, Schneider G. Artificial intelligence in drug discovery: recent advances and future perspectives. Expert Opin Drug Discov [Internet]. 2021;16(9):949–59. Available from: https://doi.org/10.1080/17460441.2021.1909567
9. Jürgen Schmidhuber. No TitleDeep learning in neural networks: An overview. Volume 61,(January 2015,):Pages 85-117.
10. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. Chem Rev. 2019;119(18):10520–94.
11. Niazi SK, Mariam Z. Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis. Pharmaceuticals. 2024;17(1):1–22.
12. Garg S, Arora K, Singh S, Nagarajan K. Artificial intelligence and machine learning in drug discovery and development. Artif Intell Age Nanotechnol. 2023;42–61.
13. Ekmekci PE, Arda B. History of Artificial Intelligence. SpringerBriefs in Ethics. 2020;(December):1–15.
14. Abbas MKG, Rassam A, Karamshahi F, Abunora R, Abouseada M. The Role of AI in Drug Discovery. ChemBioChem. 2024;25(14).
15. Chen W, Liu X, Zhang S, Chen S. Artificial intelligence for drug discovery: Resources, methods, and applications. Mol Ther Nucleic Acids [Internet]. 2023;31(March):691–702. Available from: https://doi.org/10.1016/j.omtn.2023.02.019
16. No TitleArtificial Intelligence and Machine Learning in Drug Design and Development.
17. Struble TJ, Alvarez JC, Brown SP, Chytil M, Cisar J, DesJarlais RL, et al. Current and Future Roles of Artificial Intelligence in Medicinal Chemistry

Synthesis. J Med Chem [Internet]. 2020 Aug 27;63(16):8667–82. Available from: https://doi.org/10.1021/acs.jmedchem.9b02120

18. Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, et al. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals. 2023;16(6):1–11.
19. Paul, D.; Sanap, G.; Shenoy, S.; Kalyane, D.; Kalia, K.; Tekade RKA intelligence in drug discovery and development., Drug Discov. Today 2021, 26 80–93. No Title.
20. Tabana Y, Babu D, Fahlman R, Siraki AG, Barakat K. Target identification of small molecules: an overview of the current applications in drug discovery. BMC Biotechnol [Internet]. 2023;23(1):1–19. Available from: https://doi.org/10.1186/s12896-023-00815-4
21. Schenone M, Dančík V, Wagner BK et al. T identifcation and, Nat mechanism of action in chemical biology and drug discovery., 2013;9:232–40. CB. No Title.
22. Erratum regarding Declaration of Competing Interest statements in previously published articles (AI Open (2021) 2 (43–64), (S2666651021000024), (10.1016/j.aiopen.2021.02.001)). AI Open. 2024;(xxxx):10–1.
23. 1. Jumper, J., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873) 583–589. No Title.
24. Zhou G, Rusnac DV, Park H, Canzani D, Nguyen HM, Stewart L, et al. An artificial intelligence accelerated virtual screening platform for drug discovery. Nat Commun [Internet]. 2024;15(1). Available from: http://dx.doi.org/10.1038/s41467-024-52061-7
25. Gorgulla C et al. A open source drug discovery platform enables, ultra-large virtual screens. Nature 580 663–668 (2020). No TitleGorgulla, C. et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature 580, 663–668 (2020).
26. Nacher JC, Akutsu T. Analysis on critical nodes in controlling complex networks using dominating sets. Proc - 2013 Int Conf Signal-Image Technol Internet-Based Syst SITIS 2013. 2013;649–54.
27. 5. Wallach, I. et al. (2015). AA deep convolutional neural network for bioactivity prediction in structure based drug discovery. arXiv preprint arXiv:1510. 02855. No Title.

28. Oliveira T, Silva M, Maia E, Silva A, Taranto A. Virtual Screening Algorithms in Drug Discovery: A Review Focused on Machine and Deep Learning Methods. Drugs Drug Candidates. 2023;2(2):311–34.
29. A. Srinivas Reddy, S. Priyadarshini Pati, P. Praveen Kumar, H.N. Pradeep, G. Narahari Sastry. Virtual Screening in Drug Discovery - A Computational Perspective. Curr Protein Pept Sci. 2007;8(4):329–51.
30. Process V is an in silico technique used in the drug discovery. No Title.
31. 4. Olivecrona, M. et al. (2017). No TitleMolecular de novo design through deep reinforcement learning. Journal of Cheminformatics. :1–14.
32. Methods C aided DD. Antibiotics. Biotechnol Bioeng. 1965;7(1):29–51.
33. Verma S, Pathak RK. Discovery and optimization of lead molecules in drug designing. Bioinforma Methods Appl. 2021;(October 2021):253–67.
34. Modification L. Lead Modification (or Lead Optimization) Pharmacophore (similar to SAR with sulfa drugs) Opioids as an example (morphine).
35. Zhu, Z., and Cuozzo J (2009). R article: high throughput affinity based, technologies for small-molecule drug discovery. SLAS Discov. 14 1157–1164. doi:10., 1177/1087057109350114. No Title.
36. Naithani U, Guleria V. Integrative computational approaches for discovery and evaluation of lead compound for drug design. Front Drug Discov. 2024;4(April):1–11.
37. Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv Res [Internet]. 2022;22(1):1–17. Available from: https://doi.org/10.1186/s12913-022-08272-z
38. Graul AI, Sorbera L, Pina P, Tell M, Cruces E et al. YND and, 2010;23:7–36 B– 2009. DNP. No Title.
39. Chakraborty C. Artificial Intelligence (AI) Enabled Drug Discovery and Development : Recent Advancement Everyone Talking About Artificial Intelligence.
40. V. No Title.
41. Mehta P, Titanji BK. Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality. Lancet [Internet]. 2022;400(10349):338–9. Available from: http://dx.doi.org/10.1016/S0140-6736(22)01295-8
42. ÇELİK Ö. A Research on Machine Learning Methods and Its Applications. J

Educ Technol Online Learn. 2018;1(3):25–40.

43. Sarker IH. Machine Learning: Algorithms, Real-World Applications and Research Directions. SN Comput Sci [Internet]. 2021;2(3):1–21. Available from: https://doi.org/10.1007/s42979-021-00592-x
44. Pinzi L, Bisi N, Rastelli G. How drug repurposing can advance drug discovery: challenges and opportunities. Front Drug Discov. 2024;4(August):1–9.
45. Kavalci E, Hartshorn A. Improving clinical trial design using interpretable machine learning based prediction of early trial termination. Sci Rep [Internet]. 2023;13(1):1–11. Available from: https://doi.org/10.1038/s41598-023-27416-7
46. Grimes, D. A. & Schulz KF. No TitleAn overview of clinical research: Te lay of the land.
47. Strong VE, Selby L V., Sovel M, Disa JJ, Hoskins W, Dematteo R, et al. Development and Assessment of Memorial Sloan Kettering Cancer Center's Surgical Secondary Events Grading System. Ann Surg Oncol. 2015;22(4):1061–7.
48. Aggarwal M, Madhukar M. IBM's Watson analytics for health care: A miracle made true. Cloud Comput Syst Appl Healthc. 2016;(January):117–34.
49. Taye MM. Understanding of Machine Learning with Deep Learning : Comput MDPI. 2023;12(91):1–26.
50. Gloria Kang GJ, Ewing-Nelson SR, Mackey L, Schlitt JT, Marathe A, Abbas KM SS. 乳鼠心肌提取 HHS Public Access. Physiol Behav. 2018;176(1):139–48.
51. Afrose N, Chakraborty R, Hazra A, Bhowmick P, Bhowmick M. AI-driven drug discovery and development. Futur AI Biomed Biotechnol. 2024;259–77.
52. Curie M, Training I. Accelerated Early staGe drug dIScovery. 2020;(2017).
53. Chen Y, Wang Z, Wang L, Wang J, Li P, Cao D, et al. Deep generative model for drug design from protein target sequence. J Cheminform [Internet]. 2023;15(1):1–12. Available from: https://doi.org/10.1186/s13321-023-00702-2
54. Baillif B, Cole J, McCabe P, Bender A. Deep generative models for 3D molecular structure. Curr Opin Struct Biol [Internet]. 2023;80:102566. Available from: https://doi.org/10.1016/j.sbi.2023.102566
55. Gebauer NWA, Gastegger M, Schütt KT. Generating equilibrium molecules with deep neural networks. 2018; Available from:

http://arxiv.org/abs/1810.11347

56. Chan BWGL, Lynch NB, Tran W, Joyce JM, Savage GP, Meutermans W, et al. Fragment-based drug discovery for disorders of the central nervous system: designing better drugs piece by piece. Front Chem. 2024;12(April):1–21.
57. Wallach I, Bernard D, Nguyen K, Ho G, Morrison A, Stecula A, et al. AI is a viable alternative to high throughput screening: a 318-target study. Sci Rep. 2024;14(1):1–16.
58. Jinsong S, Qifeng J, Xing C, Hao Y, Wang L. Molecular fragmentation as a crucial step in the AI-based drug development pathway. Commun Chem. 2024;7(1):1–9.
59. Li Q. Application of Fragment-Based Drug Discovery to Versatile Targets. Front Mol Biosci. 2020;7(August):1–13.
60. Kak S, Hirsh H. Quantum computing and AI A quantum leap for AI. 2023;(July). Available from: https://www.researchgate.net/profile/Abu-Rayhan-11/publication/372722253_Quantum_Computing_and_AI_A_Quantum_Leap_in_Intelligence/links/64c4bac2141074110ee2c469/Quantum-Computing-and-AI-A-Quantum-Leap-in-Intelligence.pdf%0Ahttp://www.ee.lsu.
61. - RG. Quantum Computing and AI. Int J Multidiscip Res. 2024;6(3):1–6.
62. Louhichi M, Nesmaoui R, Marwan M, Lazaar M. Shapley Values for Explaining the Black Box Nature of Machine Learning Model Clustering. Procedia Comput Sci [Internet]. 2023;220(April):806–11. Available from: https://doi.org/10.1016/j.procs.2023.03.107
63. Digital H. Explainable Artificial Intelligence (XAI): Enhancing transparency and trust in machine learning models Explainable Artificial Intelligence (XAI): Enhancing transparency and trust in machine learning models Dimple Patil. 2024;(November).
64. Ummah MS. No 主観的健康感を中心とした在宅高齢者における 健康関連指標に関する共分散構造分析Title. Sustain [Internet]. 2019;11(1):1–14. Available from: http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbeco.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_SIS

TEM_PEMBETUNGAN_TERPUSAT_STRATEGI_MELESTARI

65. Martínez-Comesaña M, Rigueira-Díaz X, Larrañaga-Janeiro A, Martínez-Torres J, Ocarranza-Prado I, Kreibel D. Impact of artificial intelligence on assessment methods in primary and secondary education: Systematic literature review. Rev Psicodidáctica (English ed). 2023;28(2):93–103.
66. Celik I, Dindar M, Muukkonen H, Järvelä S. The Promises and Challenges of Artificial Intelligence for Teachers: a Systematic Review of Research. TechTrends [Internet]. 2022;66(4):616–30. Available from: https://doi.org/10.1007/s11528-022-00715-y
67. Mohammed K, Shehu A. a Review of Artificial Intelligence (Ai) Challenges and Future Prospects of Explainable Ai in Major Fields: a Case Study of Nigeria. Open J Phys Sci (ISSN 2734-2123). 2023;4(1):1–18.
68. Mirakhori F, Niazi SK. Harnessing the AI / ML in Drug and Biological Products Discovery and Development : The Regulatory Perspective. 2025;1–36.